Home/Pipeline/Undisclosed siRNA Programs

Undisclosed siRNA Programs

Obesity

Pre-clinicalActive

Key Facts

Indication

Obesity

Phase

Pre-clinical

Status

Active

Company

Moonwalk Biosciences

About Moonwalk Biosciences

Moonwalk Biosciences is a private, pre-clinical stage biotech leveraging a proprietary platform that intersects comprehensive human genetic analysis with epigenetic profiling of adipose tissue to discover novel therapeutic targets. The company has pivoted its initial epigenetic editing focus towards developing adipose-targeted siRNA therapies for obesity, with multiple candidates showing preclinical efficacy. Backed by a seasoned leadership team with experience from companies like Amgen and academic pioneers like Feng Zhang, Moonwalk is positioned to address the significant unmet need in metabolic disease through a novel biology-driven approach.

View full company profile

Therapeutic Areas

Obesity Cardiometabolic Disease

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active